HISD's new dashboard will track active COVID-19 cases. Photo by Klaus Vedfelt/Getty Images

Greater Houston parents have an important date circled and marked on their calendars: October 19. That's the day Houston Independent School District welcomes students back for in-person instruction at all schools.

However, a major point of concern and contention with area parents is the possibility of fellow students contracting, carrying, and spreading COVID-19. To that end, the district has announced a new COVID-19 dashboard to keep the community informed about the impact of the pandemic. Parents can view the COVID-19 dashboard here.

The online dashboard launched Monday, September 28, to track the number of confirmed COVID-19 students and staff cases on campuses, in an effort to display transparency, according to a press release. As of September 28, some 23 active cases are reflected on the dashboard, out of more than 222,000 students and staff.

HISD's new dashboard was developed using Texas Education Agency guidelines for reporting COVID-19. It will be updated daily, allowing users to review student and staff data by location and districtwide, according to the district. The dashboard will also include a map to clearly illustrate and mark active cases throughout the district.

All applicable privacy laws relating to the release of personal health information will be followed, according to a press release.

"As we navigate this pandemic together, we want to ensure that we are transparent as we provide crucial updates," said HISD interim superintendent, Grenita Lathan, in a statement. "This new dashboard will give our staff members and families the information they need in an accessible and easy-to-use way to make informed decisions."

For more information on HISD's reopening plan, visit the official site.

------

This article originally ran on CultureMap.

Even in light of community concerns, HISD is moving forward on its pursuit to receive a District of Innovation designation. Getty Images

Houston school board votes in favor of moving forward with innovation designation

moving forward

In the Houston Independent School District's board meeting on Thursday, May 14, the board of trustees voted in favor to begin a process that would designate HISD a District of Innovation.

The ruling allows HISD to begin the process of receiving the DOI designation and to join the almost 900 other Texas school districts with the designation, which would be implemented for the 2021-2022 school year.

The designation would allow for several exemptions from state law, including beginning the school year earlier than the fourth Monday in August, allowing flexibility in attendance requirements, and allowing for non-accredited teachers to conduct Career and Technical Education courses.

Before the HISD board discussed the motion and voted, they heard from community members who expressed concern with this particular accreditation matter during the meeting's call for community speakers. Due to COVID-19, the speakers wrote in their concerns, which were then read for the board.

Andrew Dewey, executive vice president of the Houston Federation of Teachers, asked the board to oppose the motion as the exemptions allowed by DOI aren't in themselves innovative, he says.

To allow for non-accredited CTE instructors, "the district would have to be exempted from the entire section of the law requiring certification," writes Dewey. "That action would open the door for future administration and school boards or board of managers to allow non-certified teachers in other content areas."

Several other community members voiced this concern over allowing non-accredited teachers, and another concern was timing of the motion. A few community members argued that now is not the time to pursue the DOI designation — and Trustee Elizabeth Santos of District I echoed that concern.

"Our students deserve better than to have something shoved down their throat when there's a pandemic, and we should be solely focusing on safety and instruction," Santos says in the meeting.

Trustee Anne Sung of District VII made a motion to push back voting on the matter to the board's June meeting, but the motion was struck down in a 3-6 vote. Moving forward, Sung called for the district to proceed with caution on the accreditation of teachers.

"I want to say publicly that in the plan I will be looking for extreme rigor in protecting certification in our teachers," Sung says in the meeting.

Now that the motion has passed, it has allowed HISD's Superintendent Grenita Lathan to push forward on the DOI designation. The district's next move is to create a planning committee and collect the community's concerns on the process.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Modular nuclear reactor co. NuScale Power moves into Houston market

New to Hou

The nuclear energy renaissance continues in Texas with an announcement by NuScale Power. The Oregon-based provider of proprietary and innovative advanced small modular reactor (SMR) nuclear technology announced in April it would be opening office space in Houston’s CityCentre.

“Opening this space in Houston underscores our commitment to meeting rising energy demand with safe, scalable nuclear technology,” John Hopkins, NuScale president and CEO, said in a news release. “This move expands our presence in a key market for partners, prospective customers, and stakeholders in addition to positioning us for the future as we focus on the near-term deployment of our industry-leading technology. Texas is leading the way in embracing advanced nuclear for grid resilience and industrial decarbonization, and we’re proud to expand our footprint and capabilities in this important region.”

Interest in nuclear power has been growing in recent years thanks to tensions with oil-rich nations, concerns about man-made climate change from fossil fuels, and the rapidly increasing power needs of data centers. Both Dow and Texas A&M University have announced expanded nuclear power projects in the last year, with an eye of changing the face of Texas’s energy industry through smaller, safer fission reactors.

Enter NuScale, founded in 2007 from technology developed at the University of Oregon. Their modular SMR technology generates 77 megawatts and is one of the only small modular reactors (SMR) to receive design approval from the U.S. Nuclear Regulatory Commission (NRC). These advances have led to runaway success for NuScale, whose stock has risen by more than 1,670 percent since the start of 2024.

The new operations campus in CityCentre is expected to facilitate the movement, installation and coordination of NuScale technology into the various energy systems. Typically, SMRs are used for off-grid installations, desalination operations, mining facilities and similar areas that lack infrastructure. However, the modularity means that they can be easily deployed to a variety of areas.

It comes none too soon. ERCOT projects that Texas data centers alone will require 77,965 megawatts by 2030.

---

This article first appeared on EnergyCapitalHTX.com.

Pharma giant considers Houston for $1 billion manufacturing campus

in the works

Another pharmaceutical giant is considering Houston’s Generation Park for a manufacturing hub.

According to a recent filing with the Texas Jobs, Energy, Technology and Innovation (JETI) program, Bristol Myers Squibb Co. is considering the northeast Houston management district for a new $1 billion multi-modal pharmaceutical manufacturing campus.

If approved, the campus, known as Project Argonaut, could create 489 jobs in Texas by 2031. Jobs would include operations technicians, engineering roles, administrative and management roles, production specialists, maintenance support, and quality control/assurance. The company predicts annual average wages for these positions to be around $96,000, according to the filing.

The project currently includes the 600,000-square-foot facility, but according to the filing, Bristol Myers Squibb “envisions this site growing in scale and capability well beyond its opening configuration."

The Texas JETI program offers companies temporary school property tax limitations in exchange for major capital investment and job creation. E.R. Squibb & Sons LLC applied for a 10-year tax abatement agreement in the Sheldon Independent School District.

The agreement promises a $ 1 billion investment. Construction would begin in 2027 and wrap in 2029.

“The proposed project reflects [Bristol Myers Squibb Co.’s] enduring commitment to bringing innovative medicines to patients and ensuring the long-term supply reliability they depend on,” the filing says. “The proposed project is purpose-built to support and manufacture medicines spanning multiple therapeutic areas and modalities, positioning the site as a long-term launch and commercial campus for decades to come. These medicines will provide therapies to the [Bristol Myers Squibb Co.’s] patients located in markets both nationally and internationally.”

The Fortune 100 company is considering 16 other cities for the new manufacturing facility in the Central and Eastern markets in the U.S. According to the Houston Chronicle, Bristol Myers Squibb Co is still in the “evaluation process” for its potential manufacturing site.

Last fall, Eli Lilly and Co. selected Generation Park for its $6.5 billion manufacturing plant. More than 300 locations in the U.S. competed for the factory. Read more here.

Houston health tech co. lands NIH grant for AI cancer prediction tool

fresh funding

Houston-based CellChorus and Stanford Medicine were recently awarded a Phase I Small Business Innovation Research grant for the company's AI platform to test how certain cancer patients will respond to therapies.

The funding comes from the National Cancer Institute of the National Institutes of Health. According to a filing, the grant totaled just under $400,000.

CellChorus, which spun out from the University of Houston’s Technology Bridge, has developed TIMING (Time-lapse Imaging Microscopy In Nanowell Grids), which analyzes the behavior of thousands of individual immune cells over time and can identify early indicators of treatment success or failure.

The company will work with Stanford's Dr. David Miklos and Dr. Saurabh Dahiya, who have built the Bone Marrow Transplantation and Cell Therapy Biobank. The biobank manages and stores biological samples from patients treated at their clinic and in clinical trials.

"Predicting which patients will achieve durable responses after CAR-T therapy remains one of the most important challenges in the field,” Miklos said in a news release. “We aim to uncover functional cellular signatures that can guide treatment decisions and improve patient outcomes.”

The project will specifically profile cells from patients with relapsed/refractory large B-cell lymphoma (r/rLBCL). According to CellChorus, only about half of r/rLBCL patients who receive CAR-T therapy "achieve a durable, long-term remission." Others do not respond to therapy or experience relapse.

“The sooner we know whether a cancer therapy is working, the better. To maximize patient benefit, we need technology that can provide a robust and early prediction of response to therapy. The technology needs to be scalable, cost-efficient, and capable of rapid turnaround times,” Rebecca Berdeaux, chief scientific officer of CellChorus, added in the release. “We are excited to work with Drs. David Miklos and Saurabh Dahiya and their colleagues on this very important project.”

CellChorus has previously received SBIR grants from federal agencies, including a $2.5 million award in 2024 from its National Center for Advancing Translational Sciences (NCATS) and a $2.3 million SBIR Fast-Track award from the National Institute of General Medical Sciences in 2023.